Treatment regimens and clinical response
| . | N = 496 . |
|---|---|
| Treatment status, n (%) | |
| Treatment | 478 (96%) |
| No treatment | 18 (3.6%) |
| Time to treatment (d), median (IQR) | 17 (8, 37) |
| Initial regimen, n (%) | |
| R-CHOP | 231 (48%) |
| R-EPOCH | 190 (40%) |
| R-CVP | 18 (3.8%) |
| Other | 39 (8.2%) |
| Cycles received, n (%) | |
| 1-2 | 47 (10%) |
| 3-5 | 77 (16%) |
| 6 | 289 (61%) |
| ≥7 | 60 (13%) |
| Treatment completed, n (%) | 363 (76%) |
| End-of-treatment PET/CT, n (%) | 298 (64%) |
| Initial response, n (%) | |
| CR | 307 (64%) |
| PR | 49 (10%) |
| SD | 11 (2.3%) |
| PD | 97 (20%) |
| Unknown | 14 (2.9%) |
| Evidence of R/R disease | |
| During follow-up period, n (%) | 189 (38%) |
| Receipt of subsequent therapy, n (%) | 138 (28%) |
| Response to subsequent therapy, n (%) | 69 (14%) |
| Eligibility for cell therapy, n (%) | 48 (9.7%) |
| Receipt of cell therapy, n (%) | 26 (12%) |
| Type of cell therapy, n (%) | |
| HSCT only | 14 (54%) |
| CAR-T only | 7 (27%) |
| HSCT and CAR-T | 5 (19%) |
| Vital status, n (%) | |
| Alive | 325 (66%) |
| Deceased | 171 (34%) |
| . | N = 496 . |
|---|---|
| Treatment status, n (%) | |
| Treatment | 478 (96%) |
| No treatment | 18 (3.6%) |
| Time to treatment (d), median (IQR) | 17 (8, 37) |
| Initial regimen, n (%) | |
| R-CHOP | 231 (48%) |
| R-EPOCH | 190 (40%) |
| R-CVP | 18 (3.8%) |
| Other | 39 (8.2%) |
| Cycles received, n (%) | |
| 1-2 | 47 (10%) |
| 3-5 | 77 (16%) |
| 6 | 289 (61%) |
| ≥7 | 60 (13%) |
| Treatment completed, n (%) | 363 (76%) |
| End-of-treatment PET/CT, n (%) | 298 (64%) |
| Initial response, n (%) | |
| CR | 307 (64%) |
| PR | 49 (10%) |
| SD | 11 (2.3%) |
| PD | 97 (20%) |
| Unknown | 14 (2.9%) |
| Evidence of R/R disease | |
| During follow-up period, n (%) | 189 (38%) |
| Receipt of subsequent therapy, n (%) | 138 (28%) |
| Response to subsequent therapy, n (%) | 69 (14%) |
| Eligibility for cell therapy, n (%) | 48 (9.7%) |
| Receipt of cell therapy, n (%) | 26 (12%) |
| Type of cell therapy, n (%) | |
| HSCT only | 14 (54%) |
| CAR-T only | 7 (27%) |
| HSCT and CAR-T | 5 (19%) |
| Vital status, n (%) | |
| Alive | 325 (66%) |
| Deceased | 171 (34%) |
PD, progressive disease; SD, stable disease.